Montana State University
Trial Pipeline
Impact of Haskap Berries on Recovery From High Intensity Resistance Training
NCT07344727
Rural Autistic Individuals - Supporting Expression
NCT07054866
Gut Microbiota-dependent Health Impacts of Haskap Berries
NCT06546020
Trauma and Cardiometabolic Health in an American Indian Community
NCT06878885
Creatine for Depressed Male and Female Methamphetamine Users
NCT02568878
Pilot Haskap Metabolite Timing Project
NCT06938386
Ankle Dorsiflexion Changes With Assisted Stretching Device
NCT06343506
Health Mindset as a Driver of Efficacy of a Diabetes Prevention Program in the Blackfeet Community
NCT04571723
A Trauma-Informed Approach for Positive Youth Development for Montana Students
NCT04664855
Improving Chronic Illness Management With the Apsaalooke Nation: The Baa Nnilah Project
NCT03036189
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
What the Pipeline for Montana State University Shows
According to the ClinicalTrials.gov registry, Montana State University is linked to 10 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 50% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 40% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Montana State University reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Montana State University is Microbial Colonization with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.